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Abstract: In this article, we report anticancer activity of 14 anthracenedione derivatives 
separated from the secondary metabolites of the mangrove endophytic fungi Halorosellinia 
sp. (No. 1403) and Guignardia sp. (No. 4382). Some of them inhibited potently the growth 
of KB and KBv200 cells, among which compound 6 displayed strong cytotoxicity with 
IC50 values of 3.17 and 3.21 μM to KB and KBv200 cells, respectively. Furthermore, we 
demonstrate that the mechanism involved in the apoptosis induced by compound 6 is 
probably related to mitochondrial dysfunction. Additionally, the structure-activity 
relationships of these compounds are discussed. 
Keywords:  mangrove endophytic fungi; anthracenedione derivatives; anticancer; 
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1. Introduction 
Cancer has become an increasing public health problem due to its high rates of morbidity and 
mortality. Conventional cancer chemotherapy has the limitation of multidrug resistance (MDR) caused 
by overexpression of integral membrane transporters, such as P-gp, which can efflux intracellular 
anticancer drugs thus decreasing drug accumulation. MDR cells are resistant to cytotoxic effects of 
various structurally and mechanistically unrelated chemotherapeutic agents [1–3]. Developing new 
anticancer drugs that are efficient to MDR cells is a feasible strategy to overcome MDR. 
The natural environment is still the most important supply of novel drugs despite development of 
combinatorial chemistry, which can quickly generate thousands of new chemicals. The terrestrial 
environment has been mined for drugs for many years with great success. Now humans have 
recognized that the oceans are a rich source of natural products with potential as drugs [4–6]. Many 
promising compounds of new and complicated structure types have been isolated from the oceans and 
some have been identified as leading preclinical anticancer compounds. Interestingly, marine 
microalgae, cyanobacteria, and heterotrophic bacteria living in association with invertebrates (e.g., 
sponges, tunicates, and soft corals) have been identified, or strongly suspected, as the true sources of 
many bioactive and useful constituents [7,8]. Cell sorting, culture, and molecular biological methods 
are helpful to clarify the intriguing aspect of marine metabolism [9–11]. Marine-derived fungi have 
been rich sources of structurally novel and biologically active secondary metabolites, which have 
become attractive as important resources for new chemicals in drug discovery [12,13]. As part of our 
ongoing investigations directed toward the discovery of structurally new and biologically active 
natural products from marine endophytic fungi, we studied the anthracenedione derivatives acting as 
the potent anticancer agents screened from the mangrove endophytic fungus Halorosellinia sp.   
(No. 1403) and Guignardia sp. (No. 4382). We have reported the isolation and identification of these 
compounds before [13–15]. Here, the mechanisms involving the apoptosis induced by these 
anthracenedione derivatives are investigated and discussed. Moreover, we analyze the structure-
activity relationships (SAR) of these compounds. 
2. Results and Discussion 
In this study, we investigated the anticancer activity of several anthracenedione derivatives, which 
was separated from the secondary metabolites of the mangrove endophytic fungus Halorosellinia sp. 
(No. 1403) and Guignardia sp. (No. 4382). Compounds 1–14 of 9,10-anthracenediones showed potent 
cytotoxicity to drug-sensitive parental KB cells and MDR KBv200 cells (Table 1), among which 
compound 6 displayed strong cytotoxicity with the IC50 values of 3.17 and 3.21 μM to KB and 
KBv200 cells, respectively. Anthraquinones represent a large family of compounds having diverse 
biological activities [16–18]. Herein, compound 6 displayed its cytotoxicity to KB and KBv200 cells 
(Figure 1). Mar. Drugs 2010, 8                          
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Table 1. Structures and cytotoxicity IC50 values of compound 1–14. 
O
O
R1
R3
R8
R7
R6
R5 R4
R2
 
Compound R1 R 2 R 3 R 4 R 6 R 7 R 8 Cytotoxicity  IC50 ( μM ) 
               KB  KBv200 
1  methoxy — methoxy  —  methyl  —  —  57.32  90.86 
2  hydroxy methoxy  —  hydroxy  —  methyl  —  305.14  * 
3  hydroxy —  methyl  —  —  — hydroxy  174.87  331.97 
4  hydroxy methoxy  —  hydroxy  methyl  hydroxy  —  *  * 
5  hydroxy —    hydroxy  —  methyl  —  114.09  86.45 
6  hydroxy —  methyl  —  —  —  —  3.17  3.21 
7  hydroxy —  —  —  —  — hydroxy  56.56  109.15 
8  hydroxy — hydroxy  —  —  — hydroxy  *  72.60 
9  hydroxy — hydroxy — methoxy —  methyl  38.05  34.64 
10  hydroxy — hydroxy  —  methyl  — hydroxy  *  * 
11  methoxy —  methyl  —  —  — hydroxy  *  185.68 
12  hydroxy — hydroxy  —  methyl  — methoxy  *  190.81 
13  hydroxy methoxy  —  methoxy  methyl  hydroxy  —  *  301.47 
14  hydroxy methoxy    methoxy    methyl    68.39  243.69 
* The IC50 values were more than 500.0 μM. As the positive control, adriamycin showed cytotoxicity to KB 
and KBv200 cells with the IC50 values of 0.034 and 1.894 μM, respectively. 
Figure 1. Compound 6 showed potent cytotoxicity to KB and KBv200 cells. Cytotoxicity 
was measured by 3-(4,5-Dimethyl-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay. The cells having grown for 24 h were exposed to a full range of concentrations of 
compound 6 for 68 h. After subsequent staining with MTT for 4 h, cell viability was 
assessed by Model 550 Microplate reader Results were shown as means ± SD of at least 
triplicate determinations. Each experiment was performed in three replicate wells. 
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Our results indicate that various substituting groups made their different contributions to the 
anticancer activity. It is believed that hydroxy groups perform important roles by offering hydrogen 
bonding with biomacromolecules such as proteins. At the same time, the quantity and location of 
hydroxy groups are fundamental to the activities of the compounds [19]. Compound 1, 5, 6, 7 and 9 
potently inhibited growth of KB cells and KBv200 cells. Compound 6, containing 1-hydroxy, showed 
the most potent inhibition of growth of KB cells and KBv200 cells. Interestingly, compounds with  
1-hydroxy and another hydroxy at other carbons led to the decrease of anticancer activity, such as 
compound 1, 3, 7 and 9. Compounds 4 and 10, with multiple substituting groups at different carbons, 
showed its cytotoxicity IC50 values more than 500.0 μM. Compared to compounds 4 and 10 
(containing three hydroxy groups), compound 9 has two hydroxy groups, which is probably related to 
the differences observed in IC50 values. It seems that multi-hydroxy-substitution was unfavorable to 
the cytotoxicity activity. Compound 6 exhibited similar cytotoxicity to both the drug-sensitive parental 
KB cells and the MDR KBv200 cells. Compared to KB cells, KBv200 cells showed resistance to 
compounds 1, 3, 7 and 14. 
In addition to the SAR, the mechanisms involved in the anticancer activity of compounds 1–14 is 
attractive to investigate. Anthraquinones exhibit anticancer activity through various pathways 
including inducing apotosis [18]. Indeed, compound 6 induced apoptosis in KB and KBv200 cells 
(Figure 2). After KB and KBv200 cells were treated with 12.0 μM compound 6 for 48 h, the cells were 
gathered and exposed to double staining and flow cytometry analysis. The results showed that 
apoptosis rates of drug-treated cells were 25.3 ± 3.5% and 26.4 ± 2.4% for KB and KBv200 cells, 
respectively. Thus, compared to the control experiments, compound 6 significantly increased the 
apoptosis rate in KB and KBv200 cells. To confirm the apoptosis-induction of compound 6, we carried 
out Hoechst 33258 staining assay and observed the cells by fluorescence microscopy. Control cells 
showed an even distribution of staining of homogeneous nuclei features. Apoptotic cells displayed 
typical changes of apoptosis including staining bright of condensed or fragmented nucleus (Figure 3).  
Chemotherapeutic agents can usually induce apoptosis via a mitochondrial pathway [20]. In this 
article, compound 6 treatment led to loss of mitochondrial potential (ΔΨm). Herein, DiOC6 was 
performed as the mitochondria-specific and voltage-dependent dye for determining ΔΨm, the loss of 
which is regarded as a leading important factor in the apoptotic pathway. After KB and KBv200 cells 
were treated with compound 6 at the concentrations of 0, 6.0 and 12.0 μM for 48 h, the decrease of 
ΔΨm showing was observed in a concentration-dependent manner (Figure 4A). The levels of ΔΨm 
were 83.91 ± 9.18%, 70.50 ± 5.99% of control in KB cells, 81.59 ± 6.23%, 67.49 ± 9.49% of control 
in KBv200 cells, demonstrating that compound 6 caused mitochondrial dysfunction in KB and 
KBv200 cells. Mitochondrial dysfunctions, including loss of ΔΨm, are likely to cause apoptosis 
[21,22]. Under current understanding, loss of ΔΨm causes release of cytochrosome c and sequent 
activation of caspases [23]. Indeed, release of cytochrosome c  was observed after exposure to 
compound 6 at the indicated concentrations for 48 h in a concentration-dependent manner (Figure 4B). 
Taken together, compound 6 might induce apoptosis via a mitochondrial pathway.  Mar. Drugs 2010, 8                          
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Figure 2. Compound 6 induced cell apoptosis in KB and KBv200 cells. Compound 6 
induced cell apoptosis in KB and KBv200 cells detected by Annexin V-FITC/PI double 
staining and flow cytometer assay. The right bottom quadrant represented cells stained 
mainly by Annexin-V (early apoptotic cells) and the top right quadrant represented cells 
stained by both PI and Annexin-V (late apoptotic/necrotic secondary necrosis). The top left 
quadrant represented cells stained mainly by PI and viable cells negative for both Annexin-
V and PI appeared in the left bottom quadrant. (A) KB cells exposed to 0 and   
12 μM compound 6, respectively. (B) of KBv200 cells exposed to 0 and12 μM compound 
6, respectively. (C) statistical analysis of the above results. The apoptosis rate is showed in 
the bar graph. The results represent the data of three assays (means ± SD). * P < 0.05 and 
** P < 0.01 versus the control. 
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Figure 3. Compound 6 induces morphological changes representative of apoptosis. Cell 
apoptosis induced by compound 6 was examined by Hoechst 33258 staining and observed 
under fluorescence microscope at 400 × magnification. KB cells and KBv200 cells were 
treated with compound 6 of 12.0 μM for 48 h. The apoptotic cells detected by the 
fluorescence microscopy displayed typical changes of apoptosis including staining bright 
of condensed or fragmented nucleus. Herein, treatment with adriamycin (0.1 μM for KB 
cells and 7.0 μM for KBv200 cells) for 48 h was included as the positive control. 
 
As important cancer chemotherapy drugs, anthracyclines have a wide spectrum of anticancer 
activity, and to date have already played an important role in cancer treatment [24–26]. It is well 
known that anthracyclines, such as adriamycin (ADR) and daunomycin (DAM) can intercalate into 
DNA. There is compelling evidence that cellular DNA is the primary target of these drugs [27,28]. To 
clarify whether compound 6 exerted cytotoxicity to KB cells and KBv200 cell via targeting DNA, a 
DNA binding assay was performed. The results indicated that compound 6 did not intercalate into 
DNA and implied that apoptosis induced by compound 6 might not involve DNA intercalation   
(Figure 5). Mar. Drugs 2010, 8                          
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Figure 4. Compound 6 treatment results in the loss of ΔΨm and release of cytochrome c. 
After cells were exposed to 0, 6.0 and 12.0 μM of compound 6 for 48 h, the ΔΨm was 
determined by flow cytometry. Loss of ΔΨm in KB and KBv200 cells and release of 
cytochrome c were observed in a dose-dependent manner. (A) the decrease of ΔΨm in KB 
and KBv200 cells; also, ΔΨm levels expressed as units of MFI were calculated as 
percentage of control. Results are mean ± SD of three determinations. * P < 0.05 and  
**  P < 0.01 vs. the control. (B) the release of cytochrosome c after treatment with 
compound 6 for the indicated time in KB cells and KBv200 cells, respectively. GAPDH 
detection was used to confirm equal protein loading. 
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Figure 5. Compound 6 does not intercalate into DNA. After 10.0, 20.0, 40.0, 80.0 μM 
ADR and 12.0, 24.0, 48.0, 96.0 μM compound 6 at 37 °C for 48 h, the mixture was 
subjected to electrophoresis on a 1.2% agarose gel stained with 1.5 μM EB at 60 V for  
40 min in 1 × TAE buffer and photographed under ultraviolet light. 
 
Anthracenedione derivatives have been extensively investigated for various activities and different 
mechanisms, such as inducing apoptosis, modulating G-quadruplex recognition, and inhibiting 
endothelial cell proliferation [29,30]. In this article, we focused on the cytotoxicity of anthracenedione 
derivatives compound 1–14, discussion of SAR and mechanism of inducing apoptosis. The mechanism 
involving the apoptosis induced by compound 6 is probably related to mitochondrial dysfunction. 
3. Experimental Section 
3.1. Chemicals and reagents 
3-(4,5-Dimethyl-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide (MTT) was purchased from 
Sigma Chemical Co. Compounds for MTT assays were obtained with a purity of ＞98% from the 
secondary metabolites of the mangrove endophytic fungus Halorosellinia sp. (No. 1403) and 
Guignardia sp. (No. 4382). KB and KBv200 are human epidermoid carcinoma cell lines. KBv200 
cells, the classic multidrug resistant cell line expressing high levels of P-gp, were cloned from   
drug-sensitive parental KB cells by stepwise exposure to increasing doses of vincristine (VCR) and 
ethylmethane sulfonate (EMS) mutagenesis. Compared with the KB cell line, the KBv200 cell line was 
about 100-times more resistant to VCR. KB cells and KBv200 cells, obtained from the Chinese 
Academy of Medical Sciences (Beijing, China), were cultured in RPMI 1640 medium containing   
100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS). All cells were 
maintained in a humidified atmosphere incubator containing 5% CO2 and 95% air at 37 °C [33]. 
3.2. Fermentation of fungi, extraction, isolation and identification of compounds 
Starter cultures (from Prof. L.L.P. Vrimjoed) were maintained on cornmeal seawater agar. Plugs of 
agar supporting mycelial growth were cut and transferred aseptically to a 250 mL Erlenmeyer flask 
containing 100 mL of liquidmedium (glucose 10 g/L, peptone 2 g/L, yeast extract 1 g/L, NaCl 2 g/L, 
pH 7.0). The flask was incubated at 28 °C. After shaking on a rotary shaker for 3–5 days, the Mar. Drugs 2010, 8                          
 
 
1477
mycelium was aseptically transferred to a 500 mL Erlenmeyer flask containing the culture liquid   
(200 mL). The flask was then incubated at 28 °C for 25 days. The cultures (150 L) were filtered 
through cheesecloth. The filtrate was concentrated to 5 L below 50 °C and extracted three times by 
shaking with an equal volume of ethyl acetate. The combined organic extracts were subjected to a 
silica gel column, eluting with a gradient of petroleum ether to ethyl acetate [13,14].  
NMR data were recorded on a Varian Inova-500 NB spectrometer, using DMSO or CDCl3 as 
solvent and TMS as internal standard. Mass spectra were acquired on a VG-ZAB mass spectrometer. 
IR spectra were obtained on a Nicolet 5DX-FTIR spectrophotometer [14]. 
3.3. Cell viability assay 
Cells were harvested during logarithmic growth phase and seeded in 96-well plates at a density of 
1.5 × 10
4 cells/mL in a final volume of 190 μL/well. After 24 h incubation, 10 μL of tested compounds 
covering a full range of concentrations were added to 96-well plates. After 68 h treatment, 10 μL MTT 
(10 mM stock solution of saline) was added to each well for 4 h. Subsequently, the supernatant was 
removed, and MTT crystals were dissolved with 100 μL anhydrous DMSO in each well. Thereafter, 
cell viability was measured using a Model 550 Microplate reader (BIO-RAD, USA) at 540 nm with 
655 nm as reference filter. Experiments were performed at least three times. The 50% inhibitory 
concentration (IC50) was determined as the anticancer drug concentration causing 50% reduction of 
cell viability and calculated from the cytotoxicity curves (Bliss’s software) [32]. Cell survival was 
calculated using the following formula: survival (%) = (mean experimental absorbance/mean control 
absorbance) × 100%. 
3.4. Determination of mitochondrial potential (ΔΨm) 
ΔΨm was measured by flow cytometry with the mitochondrial tracking fluorescent DiOC6. The 
cationic lipophilic fluorochrome DiOC6 is a cell permeable marker that specifically accumulates into 
mitochondria depending on ΔΨm. After exposure to tested compounds for the indicated time,   
5 × 10
5 cells were harvested, centrifuged at 1,000 rpm for 5 min, and washed once with ice-cold PBS. 
Thereafter, cells were incubated with 40 nM DiOC6 at 37 °C for 20 min in the dark. Then cells were 
washed twice, resuspended in 1 mL PBS, and analyzed on a FACS Caliber flow cytometer (Beckman-
coulter, Elite) with the excitation wavelength of 484 nm and emission wavelength of 501 nm. At least 
10,000 cells were determined for each sample. The data obtained from flow cytometry were analyzed 
by CellQuest software and expressed as mean fluorescence intensity (MFI) [31]. The expressed data 
were the results of at least three independent determinations. 
3.5. Annexin V-FITC/PI assay 
Apoptosis rate was quantified by detecting surface exposure of phosphatidylserine in apoptotic cells 
using Annexin V-FITC/PI (propidium iodide) apoptosis detection kit (BD Biosciences Clontech) 
according to the manufacturer's instruction. After KB and KBv200 cells were treated with 12 μM 
compound 6 for 48 h, the cells were collected and washed twice with cold PBS. Then, 5 × 10
5 cells 
were resuspended in 0.5 mL binding buffer containing Annexin-V (1:50 according to the Mar. Drugs 2010, 8                          
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manufacturer’s instruction) and 40 ng/sample of PI for 20 min at 37 °C in the dark. The numbers of 
viable, apoptotic and necrotic cells were quantified by flow cytometry (Beckman Coulter, Cytomics 
FC500, USA) and analysis by the CellQuest software. At least 10,000 cells were calculated for each 
sample. The apoptosis rate (%) = (the number of apoptotic cells/the number of total cells observed) × 
100% [18].  
3.6. Hoechst 33258 staining 
After treatment with or without compound 6, both floating and trypsinized adherent cells were 
collected, washed once with ice-cold PBS, fixed with 1 mL 4% paraformaldehyde for 20 min, then 
washed once with ice-cold PBS. After that, the cells were incubated in 1 mL PBS containing 10 μM 
Hoechst 33258 at 37 °C for 30 min, washed twice, and observed using fluorescence microscopy with 
standard excitation filters (Leica Dmirb, Germany) in random microscopic fields at   
400 × magnification. The experiments were performed at least three times [28]. 
3.7. Subcellular fractionation for western blot analysis of cytosolic cytochrome c 
Cells were treated with tested compounds for the indicated time and harvested by centrifugation at 
1,000 rpm for 5 min. The pellets were washed twice with ice-cold PBS, suspended with 5-fold volume 
of ice-cold cell extract buffer (20 mM Hepes–KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM 
EDTA, 1 mM EGTA, 1 mM DTT, 250 mM sucrose, 0.1 mM PMSF and 0.02 mM aprotinin) and 
incubated for 40 min at 4 °C. Then the cells were centrifuged at 1,200 rpm for 10 min at 4 °C; the 
supernatant was subsequently centrifuged at 12,000 rpm for 15 min at 4 °C and the final supernatant 
was used as cytosolic fraction. Then 5 × loading buffer (250 mM Tris-Cl (pH 6.8), 50% glycerol, 10% 
sodium dodecylsulphate, 1.25‰ bromphenol blue, 0.5 M dithiothreitol) was added to the above 
supernatant and the mixture was boiled at 100 °C for 15 min. After that, the protein solution was used 
for identification of cytosolic cytochrome c by immunoblotting with 10% SDS–PAGE and blotting 
onto PVDF membrane. The cytochrome c protein was detected by using anti-cytochrome c antibody 
(Cell Signalling, USA) in the ratio of 1:1,000 [28]. 
3.8. DNA binding assay 
ADR, which is able to intercalate into nucleic bases, was used as the positive control in the DNA 
binding assay. Briefly, 10.0, 20.0, 40.0 and 80.0 μM ADR or 12.0, 24.0, 48.0, 96.0 μM compound 6 
were incubated with pEGFPC2-H1-MDR1shDNA at 37 °C for 48 h, respectively. Then, the mixture 
was subjected to electrophoresis on a 1.2% agarose gel stained with 1.5 μM EB at 60 V for 40 min 
with 1 × TAE buffer. Observation and photography were developed with the gel imaging and analysis 
system (Vilber Lourmat, France) [28]. 
4. Conclusions 
In summary, we screened some potent antitumor agents of 9,10-anthracenediones from secondary 
metabolites of the mangrove endophytic fungus. The information stemming from the structure–activity 
relationships will constitute the basis for the design of future compounds with potentially better Mar. Drugs 2010, 8                          
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activity. Our mechanistic investigation indicates that compound 6 might induce apoptosis via a 
mitochondrial pathway. 
Acknowledgements 
We thank Xu-yi Liu (Cancer Hospital of Beijing, China) for ABCB1 overexpressing KBv200 cells 
and parental sensitive KB cells. The work was supported by grants from China National Natural 
Sciences Foundation No. 30672407, No. 30600769, 863 Project Foundation No. 2006AA09Z419 and 
Open Project Program (2009) of State Key Laboratory of Oncology in South China. 
References and Notes 
1.  Smyth, M.J.; Krasovskis, E.; Sutton, V.R.; Johnstone, R.W. The drug efflux protein, P-
glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-
dependent apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95, 7024–7029. 
2.  Ruefli, A.A.; Tainton, K.M.; Darcy, P.K.; Smyth, M.J.; Johnstone, R.W. P-glycoprotein inhibits 
caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas 
ligation. Cell Death Differ. 2002, 9, 1266–1272. 
3.  Shi, Z.; Peng, X.X.; Kim, I.W.; Shukla, S.; Si, Q.S.; Robey, R.W.; Bates, S.E.; Shen, T.; Ashby, 
C.R., Jr.; Fu, L.W.; Ambudkar, S.V.; Chen, Z.S. Erlotinib (Tarceva, OSI-774) antagonizes ATP-
binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-
mediated drug resistance. Cancer Res. 2007, 67, 11012–11020. 
4.  Cooper, E.L. Drug Discovery, CAM and Natural Products. Evid. Based Complement. Alternat. 
Med. 2004, 1, 215–217. 
5.  D'Incalci, M.; Simone, M.; Tavecchio, M.; Damia, G.; Garbi, A.; Erba, E. New drugs from the 
sea. J. Chemother. 2004, 16 (Suppl. 4), 86–89. 
6.  Simmons, T.L.; Andrianasolo, E.; McPhail, K.; Flatt, P.; Gerwick, W.H. Marine natural products 
as anticancer drugs. Mol. Cancer Ther. 2005, 4, 333–342. 
7.  Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural 
products. Nat. Rev. Drug Discov. 2009, 8, 69–85. 
8.  Gordaliza, M. Natural products as leads to anticancer drugs. Clin. Transl. Oncol. 2007, 9, 767–776. 
9.  Sufrin, J.R.; Finckbeiner, S.; Oliver, C.M. Marine-derived metabolites of S-adenosylmethionine 
as templates for new anti-infectives. Mar. Drugs 2009, 7, 401–434. 
10.  Baerga-Ortiz, A. Biotechnology and biochemistry of marine natural products. P. R. Health Sci. J. 
2009, 28, 251–257. 
11. Olano, C.; Mendez, C.; Salas, J.A. Antitumor compounds from marine actinomycetes. Mar. 
Drugs 2009, 7, 210–248. 
12.  Li, D.L.; Li, X.M.; Wang, B.G. Natural anthraquinone derivatives from a marine mangrove plant-
derived endophytic fungus Eurotium rubrum: structural elucidation and DPPH radical scavenging 
activity. J. Microbiol. Biotechnol. 2009, 19, 675–680. 
13.  Xia, X.K.; Huang, H.R.; She, Z.G.; Shao, C.L.; Liu, F.; Cai, X.L.; Vrijmoed, L.L.P.; Lin, Y.C. 
(1)H and (13)C NMR assignments for five anthraquinones from the mangrove endophytic fungus 
Halorosellinia sp. (No. 1403). Magn. Reson. Chem. 2007, 45, 1006–1009. Mar. Drugs 2010, 8                          
 
 
1480
14.  She, Z.G.; Huang, H.R.; Lin, Y.C.; Vrijmoed, L.L.P.; Jones, E.B.G. 1,4-dihydroxy-2-methoxy-7-
methylanthracene-9,10-dione. Acta Crystallogr. Sect. E 2006, 62, O3737–O3738. 
15.  Jiang, G.C.; Lin, Y.C.; Zhou, S.N.; Vrijmoed, L.L.P.; Jones, E.B.G. Studies on the Secondary 
Metabolites of Mangrove Fungus No. 1403 from the South China Sea. Acta. Scientiarum 
Naturalium Universitatis Sun yat-sen. 2000, 39, 68–72. 
16.  Tatyana, K.; Francesca, E.; Luca, Z.; Giovanni, F.; Cheng, Y.C.; Ginger, E.D.; Enzo, T. Inhibition 
of HIV-1 ribonuclease H activity by novel frangula-emodine derivatives. Med. Chem. 2009, 5, 
398–410. 
17.  Park, M.Y.; Kwon, H.J.; Sung, M.K. Evaluation of aloin and aloe-emodin as anti-inflammatory 
agents in aloe by using murine macrophages. Biosci. Biotechnol. Biochem. 2009, 73, 828–832. 
18.  Yan, Y.Y.; Su, X.D.; Liang, Y.J.; Zhang, J.Y.; Shi, C.J.; Lu, Y.; Gu, L.Q.; Fu, L.W. Emodin azide 
methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in 
caspase-8-mediated Bid cleavage. Mol. Cancer Ther. 2008, 7, 1688–1697. 
19.  Huang, H.; Jia, Q.; Ma, J.; Qin, G.; Chen, Y.; Xi, Y.; Lin, L.; Zhu, W.; Ding, J.; Jiang, H.; Liu, H. 
Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase 
inhibitors. Eur. J. Med. Chem. 2009, 44, 1982–1988. 
20. Chiu, T.H.; Lai, W.W.; Hsia, T.C.; Yang, J.S.; Lai, T.Y.; Wu, P.P.; Ma, C.Y.; Yeh, C.C.; Ho, C.C.; 
Lu, H.F.; Wood, W.G.; Chung, J.G. Aloe-emodin induces cell death through S-phase arrest and 
caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. Anticancer Res. 
2009, 29, 4503–4511. 
21.  Nadanaciva, S.; Will, Y. The role of mitochondrial dysfunction and drug safety. Idrugs 2009, 12, 
706–710. 
22. Johannsen, D.L.; Ravussin, E. The role of mitochondria in health and disease. Curr. Opin. 
Pharmacol. 2009, 9, 780–786. 
23. George, N.M.; Targy, N.; Evans, J.J.; Zhang, L.; Luo, X. Bax contains two functional 
mitochondrial targeting sequences and translocates to mitochondria in a conformational change- 
and homo-oligomerization-driven process. J. Biol. Chem. 2010, 285, 1384–1392. 
24. Rabbani, A.; Finn, R.M.; Ausio, J. The anthracycline antibiotics: antitumor drugs that alter 
chromatin structure. Bioessays 2005, 27, 50–56. 
25.  Moreno-Aspitia, A.; Perez, E.A. Anthracycline- and/or taxane-resistant breast cancer: results of a 
literature review to determine the clinical challenges and current treatment trends. Clin. Ther. 
2009, 57, 1619–1640. 
26.  Rohr, J. Comparison of multicyclic polyketides by folding analysis: a novel approach to recognize 
biosynthetic and/or evolutionary interrelationships of the natural products or intermediates and its 
exemplification on hepta-, octa-, and decaketides. J. Org. Chem. 1992, 57, 5217–5223. 
27.  Khan, F.; Sherwani, A.F.; Afzal, M. Chromosomal aberration and micronucleus studies of two 
topoisomerase (II) targeting anthracyclines. J. Environ. Biol. 2009, 30, 409–412. 
28. Zhang, J.Y.; Wu, H.Y.; Xia, X.K.; Liang, Y.J.; Yan, Y.Y.; She, Z.G.; Lin, Y.C.; Fu, L.W. 
Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive 
oxygen species-independent mitochondrial pathway and death receptor pathway. Cancer Biol. 
Ther. 2007, 6, 1413–1421. Mar. Drugs 2010, 8                          
 
 
1481
29.  Zagotto, G.; Sissi, C.; Moro, S.; Dal, Ben D.; Parkinson, G.N.; Fox, K.R.; Neidle, S.; Palumbo, M. 
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 
2,7 bis-substituted anthracenedione derivatives. Bioorg. Med. Chem. 2008, 16, 354–361. 
30. Raghava, S.; Kompella, U.B. AQ4, an antitumor anthracenedione, inhibits endothelial cell 
proliferation and vascular endothelial growth factor secretion: implications for the therapy of 
ocular neovascular disorders. Eur. J. Pharmacol. 2007, 568, 68–74. 
31.  Dai, C.L.; Tiwari, A.K.; Wu, C.P.; Su, X.D.; Wang, S.R.; Liu, D.G.; Ashby, C.R. Jr.; Huang, Y.; 
Robey, R.W.; Liang, Y.J.; Chen, L.M.; Shi, C.J.; Ambudkar, S.V.; Chen, Z.S.; Fu, L.W. Lapatinib 
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of 
ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008, 68, 7905–7914. 
32.  Zhang, J.Y.; Tao, L.Y.; Liang, Y.J.; Yan, Y.Y.; Dai, C.L.; Xia, X.K.; She, Z.G.; Lin, Y.C.; Fu, 
L.W. Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with 
involvement of GSK-3beta/beta-catenin/c-Myc pathway. Cell Cycle 2009, 8, 2444–2450. 
33.  Wang, X.H.; Jia, D.Z.; Liang, Y.J.; Yan, S.L.; Ding, Y.; Chen, L.M.; Shi, Z.; Zeng, M.S.; Liu, 
G.F.; Fu, L.W. Lgf-YL-9 induces apoptosis in human epidermoid carcinoma KB cells and 
multidrug resistant KBv200 cells via reactive oxygen species-independent mitochondrial 
pathway. Cancer Lett. 2006, 249, 256–270. 
Samples Availability: Available from the authors. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 